Tur-3

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Avian paramyxovirus 3, Avian pneumovirus, Newcastle disease virus

Pieejams no:

Boehringer Ingelheim Animal Health UK Ltd

ATĶ kods:

QI01CA02

SNN (starptautisko nepatentēto nosaukumu):

Avian paramyxovirus 3, Avian pneumovirus, Newcastle disease virus

Zāļu forma:

Suspension for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Turkeys

Ārstniecības joma:

Inactivated Viral Vaccine

Autorizācija statuss:

Authorized

Autorizācija datums:

1997-05-23

Produkta apraksts

Revised: January 2019
Amended Pages
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
TUR-3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances:
Inactivated Paramyxovirus Type 3, at least
………………………40 HAIU
Inactivated Newcastle Disease virus, at least
……………………50 PD
50
Inactivated Turkey Rhinotracheitis virus, at least………………..
9 EU
Adjuvant:
Paraffin
oil……………………………………………………………170
to 186 mg
Excipient:
Thiomersal…..………………………………………………………
15 µg
1 HAIU: q.s. to obtain a mean haemagglutination inhibiting antibody
titre of 1 in
vaccinated animals
1 EU: q.s. to obtain a positive serum by ELISA in one vaccinated
animal
50 PD
50
(50% protective dose) is performed in chickens.
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Future breeder turkeys.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of future breeder turkeys:
- as booster vaccination after priming with live vaccines against
Newcastle Disease
and Turkey Rhinotracheitis to reduce mortality and clinical signs of
Newcastle
Disease and to induce a specific seroconversion against Newcastle
Disease and
Turkey Rhinotracheitis in vaccinated birds throughout the laying
period
- as vaccination against Paramyxovirus Type 3 to reduce the decrease
in egg
production, as demonstrated by challenge at peak lay, and to induce a
specific
seroconversion against paramyxovirus type 3 throughout the laying
period.
Onset of immunity: 4 weeks after the first injection.
Duration of immunity: one laying period (demonstrated by serology).
Revised: January 2019
Amended Pages
Page 2 of 5
4.3
CONTRA-INDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Vaccinate only healthy animals.
Apply usual aseptic p